United Therapeutics Corp (UTHR) plunge -16.25% in a week: will this be a lucky break through?

As on Wednesday, United Therapeutics Corp (NASDAQ: UTHR) started slowly as it slid -10.80% to $318.89, before settling in for the price of $357.50 at the close. Taking a more long-term approach, UTHR posted a 52-week range of $221.53-$417.82.

The Healthcare sector firm’s twelve-monthly sales growth has been 12.77% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was 8.15%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 16.98%. This publicly-traded company’s shares outstanding now amounts to $44.62 million, simultaneously with a float of $43.80 million. The organization now has a market capitalization sitting at $14.24 billion. At the time of writing, stock’s 50-day Moving Average stood at $361.65, while the 200-day Moving Average is $342.31.

United Therapeutics Corp (UTHR) Ownership Facts and Figures

Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. United Therapeutics Corp’s current insider ownership accounts for 1.89%, in contrast to 100.27% institutional ownership. According to the most recent insider trade that took place on Feb 24 ’25, this organization’s PRESIDENT AND COO sold 10,000 shares at the rate of 360.76, making the entire transaction reach 3,607,555 in total value, affecting insider ownership by 0. Preceding that transaction, on Feb 18 ’25, Company’s PRESIDENT AND COO sold 10,000 for 371.05, making the whole transaction’s value amount to 3,710,499. This particular insider is now the holder of 0 in total.

United Therapeutics Corp (UTHR) Earnings and Revenue Records

Wall Street market experts anticipate that the next fiscal year will bring earnings of 6.65 per share during the current fiscal year.

United Therapeutics Corp’s EPS increase for this current 12-month fiscal period is 16.98% and is forecasted to reach 30.32 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 11.62% through the next 5 years, which can be compared against the 8.15% growth it accomplished over the previous five years trading on the market.

United Therapeutics Corp (NASDAQ: UTHR) Trading Performance Indicators

Let’s observe the current performance indicators for United Therapeutics Corp (UTHR). It’s Quick Ratio in the last reported quarter now stands at 4.41. The Stock has managed to achieve an average true range (ATR) of 13.84. Alongside those numbers, its PE Ratio stands at $14.01, and its Beta score is 0.62. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 5.17. Similarly, its price to free cash flow for trailing twelve months is now 15.85.

In the same vein, UTHR’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 22.77, a figure that is expected to reach 6.77 in the next quarter, and analysts are predicting that it will be 30.32 at the market close of one year from today.

Technical Analysis of United Therapeutics Corp (UTHR)

Through scrutinizing the latest numbers posted by the [United Therapeutics Corp, UTHR], it can be observed that its last 5-days Average volume of 0.84 million was better the volume of 0.4 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 22.87% While, its Average True Range was 15.73.

Raw Stochastic average of United Therapeutics Corp (UTHR) in the period of the previous 100 days is set at 10.42%, which indicates a major fall in contrast to 15.12% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 55.99% that was higher than 34.18% volatility it exhibited in the past 100-days period.